A new therapy to prevent
progression to severe ARDS
Acute respiratory distress syndrome (ARDS) is a life-threatening pulmonary dysfunction seen in intensive care patients, triggered by viral/bacterial infections, trauma, surgery, or blood transfusions. Currently, no effective pharmaceutical therapy for ARDS exist. The overall goal of the COVend Research and Innovation Action is to provide a new effective therapy for the clinical management of ARDS in mild and moderate stages, including the prevention of progression to severe disease. We aim to achieve this by testing a promising medication, the peptide FX06, in a placebo-controlled, multinational Phase II study in mild and moderate ARDS cases related to SARS-COV-2 or other aetiologies.
The aim of the COVend consortium is to deliver a new effective therapy against endothelial damage in ARDS for the clinical management of COVID-19 and other diseases.
Some of the technologies involved in the process are OMICs technologies for biomarker profiling, research on endothelial cell damage and AI for Data Analytics and modelling.
COVend brings together an outstanding consortium of 13 partners from 11 countries with excellent scientific, clinical and organisational expertise to deliver IXION 2.0 study.
The clinical trial is the centrepiece of COVend’s work to make FX06 a viable therapy for the clinical management of ARDS in mild and moderate stages, including the prevention of progression to severe disease.
COVend involves partners from all over Europe, with a variety of clinical sites based in different European countries, enabling the delivery of FX06 as a promising candidate to prevent endothelial damage in ARDS for the clinical management of COVID-19 and other diseases during mild and moderate stages. Hear from some COVend partners and discover how COVend is making a difference today!
On the 13th of November, the consortium member of our partner institution UMCG, Clazinus Veijer, presented his poster “Lessons learned from model-based economic evaluations of COVID-19 treatments under pandemic circumstances: results from a systematic review ” at ISPOR Europe 2023. The poster highlighted results from a systematic review of various methodological characteristics of model-based economic evaluations of COVID-19 treatments.
Exciting research from COVend presented at the joint conference of the Société Française d’Immunologie & Deutsche Gesellschaft für Immunologie in Strasbourg!
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.
FOR INQUIRIES, PLEASE SEND US AN EMAIL AT [email protected]
© accelopment Schweiz AG · [email protected] · ISO 9001 certified · Read our Privacy Policy
